Invasive lobular carcinoma (ILC) has a different treatment response from invasive ductal carcinoma (IDC). We assessed whether perioperative chemotherapy was associated with improved prognosis in patients with ILC. Retrospective data of women who underwent surgery for ILC were extracted from the SEER database. Subjects were divided into non‐chemotherapy and chemotherapy groups. Overall, 10 537 patients were included, and 2107 patients were stratified into each group after propensity score matching. Perioperative chemotherapy significantly improved 10‐year survival rates for ILC, particularly in patients with large tumor size and lymph node metastases. Perioperative chemotherapy is effective for ILC patients with proper selection.

中文翻译：

---

新辅助化疗和辅助化疗对浸润性小叶癌的影响：SEER数据的倾向得分匹配分析。

浸润性小叶癌（ILC）与浸润性导管癌（IDC）有不同的治疗反应。我们评估了围手术期化疗是否与ILC患者的预后改善相关。从SEER数据库中提取了接受ILC手术的妇女的回顾性数据。将受试者分为非化学疗法组和化学疗法组。总体上，纳入10 537例患者，并在倾向评分匹配后将2107例患者分为两组。围手术期化疗显着提高了ILC的10年生存率，特别是在肿瘤大且有淋巴结转移的患者中。围手术期化疗对选择适当的ILC患者有效。